MedTrace Logo

A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU)

NCT07372924 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2026-08-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Tegileridine Fumarate lnjection for prolonged abirritation(48h to 72h) during mechanical ventilation in the ICU.

Conditions

  • Abirritation in the ICU

Interventions

DRUG

Tegileridine Fumarate lnjection

Tegileridine Fumarate lnjection; low dose

DRUG

Tegileridine Fumarate lnjection

Tegileridine Fumarate lnjection; high dose

DRUG

Remifentanil Hydrochloride for Injection

Remifentanil Hydrochloride for Injection

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-24
Primary Completion
2026-08-14
Completion
2026-08-14

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07372924 on ClinicalTrials.gov